ObsEva SA
Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, announced today that its board of directors approved on February 10, 2021 an increase of its share capital from 69,629,347 to 81,220,471 through the issue of 11,591,124 new registered shares at an issue price of 1/13 of a Swiss Franc each, after registration of 3,406,480 new shares issued out of the company’s conditional share capital. The 11,591,124 new shares, to be issued out of the company’s authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around February 18, 2021. The transaction has been decided to provide the group with additional treasury shares that can be used in the future to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving IVF outcomes. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alvotech4.7.2025 01:02:13 CEST | Press release
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
RIB Software3.7.2025 21:17:25 CEST | Press release
RIB Software Recognized as a Leader for Construction Management Software by Independent Research Firm
Solvay S.A.3.7.2025 18:00:00 CEST | Press release
Participation notification by Morgan Stanley
Siili Solutions Oyj3.7.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 3.7.2025
Virtune AB (Publ)3.7.2025 15:29:54 CEST | Press release
Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for June 2025 of its Virtune Crypto Top 10 Index ETP - the first crypto index ETP in the Nordics
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom